Search for content, post, videos

Alligator Bioscience restructures

Søren Bregenholt
The company plans to restructure and reduce its workforce by 20-25%, with expected annual costs savings of SEK 20 million. "Over the last 12 months our OPTIMIZE-1 trial evaluating our lead asset mitazalimab in pancreatic cancer has delivered two sets of highly encouraging interim data as well as
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.